Management Concepts of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) Among Chinese Physicians
Recruiting now
Conditions studied: Liver Disease
In brief
This study is a cross-sectional survey-based study. The main goal of this study is to investigate the attitudes, perceptions, and clinical practice in assessing liver fibrosis following a metabolic dysfunction-associated steatotic liver disease (MASLD) diagnosis, and the management of MASLD patients among Chinese physicians in the departments of endocrinology / hepatology / infection / gastroenterology in Grade IIIA hospitals in provincial capitals or municipalities.
Key facts
- Study ID
- NCT07682363
- Run by
- Novo Nordisk A/S
- People needed
- 470
- Starts
- 2026-06-03
- Expected to finish
- 2027-02-23
- Last updated by the study team
- 2026-07-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Has provided informed consent.
- Registered clinical practice location in provincial capital or municipality.
- Physician with a license for clinical practice.
- Employed in the Department of Endocrinology, Hepatology, Infection or Gastroenterology.
- Hospital level: Grade IIIA hospital.
- Hold a professional title of associate chief physician or above, or senior attending physician (as an attending physician for more than or equal to (≥) 3 years).
- Conducts outpatient clinics for at least 1 half-days per week.
- The patient load of MASLD/MASH per month in the department should be:
- a. Endocrinology ≥20 patients per month
- b. Hepatology/Gastroenterology/ Infectious ≥30 patients per month
You may not qualify if…
- Participants will be excluded if they have unwillingness precluding adequate cooperation, fail to complete the questionnaire, or submit questionnaires verified as invalid.
Where it is running
- Novo Nordisk Investigational site — Beijing, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.